Ozempic side effects

The label's table counts reactions reported by at least 5 in 100 people and more often than on placebo, pooled from two placebo-controlled trials with 521 people on Ozempic over a mean of 32.9 weeks. Every row below is from that table, at the 0.5 mg dose and the 1 mg dose, out of every 100 people, against 100 on placebo (Prescribing Information).

• Nausea: 16 at 0.5 mg and 20 at 1 mg, against 6 on placebo
• Vomiting: 5 and 9, against 2
• Diarrhea: 9 and 9, against 2
• Abdominal pain: 7 and 6, against 5
• Constipation: 5 and 3, against 2

Below the table's cutoff, the label lists indigestion in about 3 in 100, burping in 1 to 3, reflux in about 2, and gas and gastritis at 1 in 100 or fewer, at or below the placebo rate (Prescribing Information). Counting every stomach-related reaction together, 33 in 100 on 0.5 mg and 36 in 100 on 1 mg had at least one, against 15 in 100 on placebo (Prescribing Information). Three in 100 on 0.5 mg and about 4 in 100 on 1 mg stopped Ozempic because of them, against fewer than 1 in 100 on placebo (Prescribing Information).

The cutoff on this table is 5 in 100. The Wegovy label reports at 2 in 100, so a shorter list means a narrower cutoff was used, and it says nothing about which drug is easier to take (Wegovy Prescribing Information).

Other things the label puts a number on: injection site reactions in 0.2 in 100 people on Ozempic, gallstones in 1.5 in 100 on 0.5 mg and 0.4 in 100 on 1 mg with none reported on placebo, adjudicated acute pancreatitis at 0.3 patients per 100 years of exposure against 0.2 on comparators, and a mean resting heart rate increase of 2 to 3 beats per minute (Prescribing Information).

The label puts the timing in one sentence. Most reports of nausea, vomiting, and diarrhea came during dose escalation (Prescribing Information). Novo Nordisk says the same thing to patients, that stomach effects can happen when starting Ozempic or when increasing the dose (Ozempic.com).

The label stops there. It does not say those effects fade with time, and nothing on this page will say it either. What it does give is a schedule with pauses built into it: 0.25 mg once weekly for 4 weeks, then 0.5 mg, then 1 mg after at least 4 weeks on 0.5 mg, then 2 mg after at least 4 weeks on 1 mg, up to a maximum of 2 mg once weekly (Prescribing Information). The label says that escalation exists to reduce the risk of stomach reactions, and the pace of it belongs to your prescriber (Prescribing Information).

The label gives a small number of practical instructions, and these are the ones that come up in the first weeks.

• Same day each week. Take it on the same day each week, at any time of day, with or without meals (Prescribing Information). You can move the day as long as at least 2 days, more than 48 hours, sit between two doses (Prescribing Information).
• A missed dose. Take it as soon as possible within 5 days of the missed dose. If more than 5 days have passed, skip it and take the next one on the regularly scheduled day (Prescribing Information). MedlinePlus gives the same 5-day window for the diabetes indication (MedlinePlus).
• Where it goes. Inject under the skin of the abdomen, thigh, or upper arm, and use a different injection site each week when you stay in the same body region (Prescribing Information). Never mix it with insulin, and if the two go in the same body region the injections should not sit next to each other (Prescribing Information).
• The pen is yours alone. Do not share it with anyone, even if the needle has been changed (Medication Guide).
• Drink fluids. Diarrhea, nausea, and vomiting can cost you fluids, and the label ties dehydration to kidney problems (Medication Guide).

The smaller-meals and bland-food advice you will see on other pages is not in the prescribing information or the Medication Guide. Novo Nordisk publishes it on the Ozempic site instead (Ozempic.com).

The Medication Guide bound into the May 2026 label carries its own revision date of January 2025, and it sorts symptoms by how fast to move. These are its lines in plain form.

• Stop and get medical help right away: swelling of the face, lips, tongue, or throat, trouble breathing or swallowing, a severe rash or itching, fainting or dizziness, or a very rapid heartbeat (Medication Guide).
• Stop and call your prescriber right away: severe pain in your stomach area that will not go away, with or without vomiting, sometimes felt through to the back (Medication Guide).
• Tell your prescriber right away: pain in your upper stomach, fever, yellowing of the skin or eyes, or clay-colored stools, which can be symptoms of gallbladder problems (Medication Guide).
• Tell your prescriber right away: nausea, vomiting, or diarrhea that does not go away (Medication Guide).
• Tell your prescriber: a lump or swelling in your neck, hoarseness, trouble swallowing, or shortness of breath, which can be symptoms of thyroid cancer (Medication Guide).
• Tell your prescriber: stomach problems that are severe or will not go away, and any change in your vision during treatment (Medication Guide).
• Tell every provider you see that you take Ozempic before surgery or any other procedure, because it may increase the chance of food getting into your lungs (Medication Guide).
• For too much Ozempic, call your prescriber or the Poison Help line at 1-800-222-1222, or go to the nearest emergency room right away (Medication Guide). Call 911 if someone has collapsed, had a seizure, has trouble breathing, or cannot be woken (MedlinePlus).

Two parts of this label rarely come up at the pharmacy counter, and both are worth reading before the first follow-up.

Low blood sugar is the first. In the 30-week trial of Ozempic on its own, severe hypoglycemia was reported by nobody in any arm, and documented symptomatic lows at or below 70 mg/dL were reported by about 2 in 100 on 0.5 mg and 4 in 100 on 1 mg, against none on placebo (Prescribing Information). Added to basal insulin over 30 weeks, those documented lows were reported by 17 in 100 on 0.5 mg and 30 in 100 on 1 mg, against 15 in 100 on placebo (Prescribing Information). The Medication Guide says the risk is higher when Ozempic is taken with insulin or a sulfonylurea, and it lists dizziness or light-headedness, blurred vision, anxiety or irritability or mood changes, sweating, slurred speech, hunger, confusion or drowsiness, shakiness, weakness, headache, a fast heartbeat, and feeling jittery as the symptoms to know (Medication Guide).

The eyes are the second. In a 2-year trial in people with type 2 diabetes and high cardiovascular risk, diabetic retinopathy complications occurred in 3.0 in 100 on Ozempic against 1.8 in 100 on placebo, and the gap was wider among people who already had retinopathy at the start, 8.2 against 5.2 (Prescribing Information). The label adds that rapid improvement in blood sugar control has been associated with a temporary worsening of diabetic retinopathy (Prescribing Information).

I never change your dose, never tell you to skip one, and never diagnose. What I do is ask every day how the nausea is, keep your answers with their dates, and when your pharmacy printout is on file hold what you tell me against its stop-and-call list so a bad turn gets noticed on the day it happens. I also keep shot day and the label's 5-day window against your real calendar, because a rule in a leaflet only helps if someone applies it to your actual week.

No clinician reviewed this page. It restates the FDA prescribing information, the Medication Guide, Novo Nordisk's Ozempic side-effects page, and MedlinePlus, linked below, and those are the documents to trust over anything here.